NCT05635331Completed
Real-world Dapagliflozin Experience in Patients With Heart Failure in Greece
Early Treatment of Heart Failure: a Non-interventional Observational Study Program of Patients With Heart Failure and Initiated on Dapagliflozin (EVOLUTION-HF - GREECE)
Source: ClinicalTrials.gov · Last updated 24 Nov 2025
Brief summary (registry, in English)
Heart failure (HF) is a global, public health issue that affects more than 63 million people worldwide. Despite advancements in treatment, a HF diagnosis still leads to significant morbidity and mortality. Dapagliflozin has been approved by both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), in May 2020 and November 2020 respectively, for HF with reduced ejection fraction (HFrEF). The overall aim of this study is to describe the characteristics of patients initiating dapagliflozin for the treatment of HFrEF and to provide early insights into real-world dapagliflozin treatment patterns as well as patient-reported outcomes (PROs) including quality of life.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 257 (actual)
- First submitted
- 23 Nov 2022
- Start date
- 28 Dec 2022
- Primary completion date
- 3 Dec 2024
- Lead sponsor
- AstraZeneca
- Diseases
- Heart failure
- NCT number
- NCT05635331
What you commit to
- Study type: Observational
- Participants enrolled: 257
- From 28 Dec 2022 to the primary completion date, 3 Dec 2024
- 7 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Diagnosis of Type 1 diabetes prior to enrolment
Other illness
- Initiation of dapagliflozin outside of local Heart Failure label
Lab values
- Prior treatment with dapagliflozin or other Sodium Glucose co-transporter 2 inhibitor treatment
Other
- Patient is enrolled less than 14 days or more than 60 days following initiation of dapagliflozin
Who the study is looking for
- Age ≥18 years as of study index date; the study index date is the date of initiation of treatment with dapagliflozin
- Patient received/receiving treatment with dapagliflozin for Heart Failure with reduced Ejection Fraction in accordance with the local dapagliflozin product label
- Signed and dated informed consent prior to enrolment in the study
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (7)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Research Site Coordinator of this site? Confirm its status | Alexandroupoli | Greece | Unknown status |
| Research Site Coordinator of this site? Confirm its status | Athens | Greece | Unknown status |
| Research Site Coordinator of this site? Confirm its status | Chania | Greece | Unknown status |
| Research Site Coordinator of this site? Confirm its status | Heraklion | Greece | Unknown status |
| Research Site Coordinator of this site? Confirm its status | Ioannina | Greece | Unknown status |
| Research Site Coordinator of this site? Confirm its status | Pátrai | Greece | Unknown status |
| Research Site Coordinator of this site? Confirm its status | Thessaloniki | Greece | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.